Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RB-associated KRAB zinc finger protein (RBAK) is a member of the KRAB-containing zinc finger transcription factor family, characterized by an N-terminal KRAB (Krüppel-associated box) domain functioning as a strong transcriptional repressor and a C2H2 zinc finger domain that mediates sequence-specific DNA binding[1][2][3]. KRAB zinc finger proteins are vertebrate-specific, modular proteins that frequently modulate gene transcription by recruitment of corepressors and may participate in diverse biological processes including cell differentiation, cell proliferation, apoptosis, nucleolar maintenance, and cell cycle arrest[1][2]. The RBAK gene product is widely expressed and may interact with the retinoblastoma protein (RB), a well-known tumor suppressor, linking it to potential roles in cell cycle regulation and tumorigenesis[1][3]. No drugs are currently known to target RBAK directly, and its utility as a therapeutic target, biomarker, or safety concern in human therapy has not been established.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RB-associated KRAB zinc finger protein (RBAK).